De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control " always " matter?

被引：0
作者：
Lorini, L. [1 ,8 ]
Gili, R. [2 ]
Salvestrini, V. [3 ]
Morelli, I. [4 ]
Smussi, D. [5 ]
Petrelli, F. [6 ]
Bonomo, P.
Bossi, P. [1 ,7 ]
机构：
[1] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Via Manzoni 56, I-20089 Milan, Italy
[2] IRCCS Osped Policlin San Martino, Med Oncol Unit, I-16132 Genoa, Italy
[3] Univ Florence, Radiat Oncol Unit, Azienda Osped Univ Careggi, Florence, Italy
[4] Univ Florence, Dept Expt & Clin Biomed Sci, Radiat Oncol Unit, Azienda Osped Univ Careggi, Florence, Italy
[5] Univ Brescia, Dept Med & Surg Specialties, Med Oncol Unit, Radiol Sci & Publ Hlth,ASST Spedali Civil, I-25123 Brescia, Italy
[6] ASST Bergamo Ovest, Oncol Unit, Treviglio, Italy
[7] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy
[8] Via Manzoni 56,0282241, I-20089 Rozzano, Italy
来源：
ORAL ONCOLOGY | 2024年 / 152卷
关键词：
De novo metastatic head and neck squamous; cell carcinoma; Radiation; Immunotherapy; Quality of Life; CLINICAL-PRACTICE GUIDELINES; NASOPHARYNGEAL CARCINOMA; RADIATION-THERAPY; OPEN-LABEL; CHEMOTHERAPY; DIAGNOSIS; SURVIVAL; CARE;
D O I：
10.1016/j.oraloncology.2024.106768
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
De novo metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) constitutes 10% of recurrent/metastatic (RM) cases. Radiotherapy (RT) has a crucial role in the treatment of locally advanced HNSCC, however its application on RM diseases is still limited. The advent of immune checkpoint inhibitors (ICIs) improves the survival of RM HNSCC, however median overall survival is still limited. Integration of locoregional RT with ICIs in de novo metastatic HNSCC represents a promising treatment option. This perspective aims to explore the role of the combination of locoregional and systemic treatment in improving outcomes for synchronous de novo metastatic HNSCC patients and highlights the principal crucial point in decision making.
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Haddad, Robert, I
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07): : 982 - 984
  • [32] Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study
    Zeng, Fujuan
    Lu, Tianzhu
    Xie, Fei
    Chen, Lizhi
    Zhang, Lin
    Su, Yong
    Yu, Zhongren
    Xiao, Yun
    Ao, Fan
    Li, Guoqing
    Chen, Zhiping
    Gong, Xiaochang
    Li, Jingao
    TRANSLATIONAL ONCOLOGY, 2021, 14 (11):
  • [33] Combined Cetuximab and Reirradiation for Locoregional Recurrent and Inoperable Squamous Cell Carcinoma of the Head and Neck
    Balermpas, Panagiotis
    Hambek, Markus
    Seitz, Oliver
    Roedel, Claus
    Weiss, Christian
    STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 (12) : 775 - 781
  • [34] Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma
    Due, A. K.
    Vogelius, I. R.
    Aznar, M. C.
    Bentzen, S. M.
    Berthelsen, A. K.
    Korreman, S. S.
    Kristensen, C. A.
    Specht, L.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 671 - 676
  • [35] Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma
    Grossberg, Aaron J.
    Chamchod, Sasikarn
    Fuller, Clifton D.
    Mohamed, Abdallah S. R.
    Heukelom, Jolien
    Eichelberger, Hillary
    Kantor, Michael E.
    Hutcheson, Katherine A.
    Gunn, G. Brandon
    Garden, Adam S.
    Frank, Steven
    Phan, Jack
    Beadle, Beth
    Skinner, Heath D.
    Morrison, William H.
    Rosenthal, David I.
    JAMA ONCOLOGY, 2016, 2 (06) : 782 - 789
  • [36] New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
    Alberti, Andrea
    Lorini, Luigi
    Ravanelli, Marco
    Perri, Francesco
    Vinches, Marie
    Rondi, Paolo
    Romani, Chiara
    Bossi, Paolo
    VACCINES, 2022, 10 (06)
  • [37] Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Moskovitz, Jessica
    Moy, Jennifer
    Ferris, Robert L.
    CURRENT ONCOLOGY REPORTS, 2018, 20 (02)
  • [38] Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
    Borcoman, Edith
    Marret, Gregoire
    Le Tourneau, Christophe
    CANCERS, 2021, 13 (11)
  • [39] Oligometastasis in Head and Neck Squamous Cell Carcinoma
    Moon, Dominic H.
    Sher, David J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (04): : 803 - 811
  • [40] Immunotherapy for squamous cell carcinoma of the head and neck
    Yokota, Tomoya
    Homma, Akihiro
    Kiyota, Naomi
    Tahara, Makoto
    Hanai, Nobuhiro
    Asakage, Takahiro
    Matsuura, Kazuto
    Ogawa, Takenori
    Saito, Yuki
    Sano, Daisuke
    Kodaira, Takeshi
    Motegi, Atsushi
    Yasuda, Koichi
    Takahashi, Shunji
    Tanaka, Kaoru
    Onoe, Takuma
    Okano, Susumu
    Imamura, Yoshinori
    Ariizumi, Yosuke
    Hayashi, Ryuichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (10) : 1089 - 1096
12345